Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Current Deferred Revenue (2016 - 2024)

Lifecore Biomedical, Inc. \De\ (LFCR) has 14 years of Current Deferred Revenue data on record, last reported at $9.0 million in Q4 2024.

  • For Q4 2024, Current Deferred Revenue rose 8.52% year-over-year to $9.0 million; the TTM value through Nov 2024 reached $9.0 million, up 8.52%, while the annual FY2024 figure was $10.6 million, 51.28% up from the prior year.
  • Current Deferred Revenue reached $9.0 million in Q4 2024 per LFCR's latest filing, down from $10.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $10.6 million in Q2 2024 and bottomed at $287000.0 in Q2 2021.
  • Average Current Deferred Revenue over 5 years is $3.4 million, with a median of $1.4 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: tumbled 76.67% in 2020, then soared 1150.81% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $644000.0 in 2020, then surged by 80.12% to $1.2 million in 2021, then crashed by 36.98% to $731000.0 in 2022, then skyrocketed by 1035.43% to $8.3 million in 2023, then increased by 8.52% to $9.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $9.0 million in Q4 2024, $10.6 million in Q2 2024, and $3.2 million in Q1 2024.